2024-04-18 20:01:11
Supplied Remsima SC to Denmark for one year
Danish authorities establish new tender for infliximab SC formulation
Northern European influence increases with expansion into Denmark after Norway
“Proving the competitiveness of Remsima SC throughout the world”
Celltrion succeeded in winning a national bid for the world’s only infliximab subcutaneous injection (SC) formulation treatment, ‘Remsima SC’, in Denmark, a major country in Northern Europe.
Celltrion announced on the 18th that it will supply Remsima SC to Denmark starting this month for the next year. It is assessed that the company has laid the foundation for market expansion in the Northern European region by winning orders in Denmark in just over two months following winning the Norwegian national tender in February.
It has been reported that the Danish government has established a separate national bidding category for the subcutaneous injection form of infliximab. In this field, Celltrion Remsima SC is said to have won the contract this time by bidding alone without competition. Thanks to its proven marketability and efficacy, an independent distribution channel has been formed in one country. In general, since the SC formulation is more expensive than the intravenous (Ⅳ) formulation, it is expected to have a positive effect on performance improvement.
In Denmark, Remsima SC will be sold directly by Celltrion Denmark. It is said that marketing activities are being prepared to expand product prescriptions immediately after launch. We plan to secure actual prescription cases and carry out activities to increase product preference among doctors and patients. As prescription data collected from medical sites affects not only Denmark but also targeting neighboring Nordic countries, the plan is to focus on strengthening the network to smoothly secure related data. We also plan to expand human resources at local corporations.
A Celltrion official said, “The Northern European region is characterized by close academic exchanges between neighboring countries, so the success of winning bids from Norway and Denmark can be seen as laying a solid foundation for expanding the influence of Remsima SC.” He added, “Last month in the US, “The competitiveness and efficacy of Remsima SC are being proven globally as it has been launched as a new drug (Zimpentra) and is well on its way to entering major European countries,” he said.
Kim Min-beom, Donga.com reporter mbkim@donga.com
-
- great
- 0dog
-
- I’m so sad
- 0dog
-
- I’m angry
- 0dog
-
- I recommend it
- dog
Hot news now
2024-04-18 20:01:11